Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options

Area of Science:

• Neurology
• Immunology
• Pediatrics

Background:

• Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory demyelinating disease of the central nervous system.
• MS is increasingly diagnosed in adolescents, typically around age 15, presenting mainly as the relapsing-remitting form.
• The etiology of MS is multifactorial, involving autoimmune, genetic, and environmental factors.

Approach:

• Therapeutic strategies for pediatric MS encompass relapse management and long-term immunomodulatory and symptomatic treatments.
• Relapse treatment involves high-dose intravenous corticosteroids, intravenous immunoglobulins, and plasmapheresis.
• Multidisciplinary care involving pediatric neurologists, ophthalmologists, psychologists, and other specialists is crucial.

Key Points:

• Immunomodulatory drugs are the cornerstone of MS therapy, categorized into first-line (e.g., interferon beta, glatiramer acetate) and second-line (e.g., natalizumab, fingolimod) treatments.
• While early immunomodulatory therapy benefits adults with MS, its efficacy in pediatric populations requires further investigation.
• Pediatric MS presents diagnostic and therapeutic challenges, necessitating ongoing research.

Conclusions:

• Effective management of pediatric MS requires a comprehensive, multidisciplinary approach.
• Further studies are essential to establish optimal immunomodulatory treatment protocols for children with MS.
• Early diagnosis and intervention remain critical challenges in pediatric multiple sclerosis care.